Caring Brands, Inc. - Common Stock (CABR)

Caring Brands Inc. (Nasdaq: CABR ) has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth. CABR intends to launch a total of 5 products over the next 2 years in addition to in-licensing additional products. CABR management has a successful track record of strategic acquisitions, rapid product development, IP development and product licensing. Revenues from the sales of Hair Enzyme Booster for the treatment of hair loss, and Photocil for the treatment of psoriasis and vitiligo, are currently being generated by direct sales in the US and licensees in India. Additional product opportunities include CB-101 for the treatment of eczema, NoStingz, a sunscreen that prevents jellyfish stings.

Caring Brands (NASDAQ: CABR) closed its underwritten U.S. public offering of 1,000,000 shares of common stock at $4.00 per share for gross proceeds of about $4 million before underwriting discounts and expenses, completing the Company’s uplisting to the Nasdaq Capital Market, where its shares began trading on Nov. 13, 2025. Caring Brands granted the underwriter a 45-day option to purchase up to 150,000 additional shares and intends to use net proceeds for general working capital, marketing and sales of its proprietary products, and repayment of certain debt.

Caring Brands (NASDAQ: CABR) closed its underwritten U.S. public offering of 1,000,000 shares of common stock at $4.00 per share for gross proceeds of about $4 million before underwriting discounts and expenses, completing the Company’s uplisting to the Nasdaq Capital Market, where its shares began trading on Nov. 13, 2025. Caring Brands granted the underwriter a 45-day option to purchase up to 150,000 additional shares and intends to use net proceeds for general working capital, marketing and sales of its proprietary products, and repayment of certain debt.